$SKYE
Skye Bioscience, Inc. Stock $skye

$skye Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000151655124000110 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$4.639M	$2.240M
YoY Change		107.1%	96.39%
% of Gross Profit
Research & Development		$4.883M	$1.255M
YoY Change		289.22%	-29.58%
% of Gross Profit
Depreciation & Amortization		$47.52K	$30.00K
YoY Change		58.4%	4.13%
% of Gross Profit
Operating Expenses		$4.969M	$24.71M
YoY Change		-79.89%	745.43%
Operating Profit		-$4.969M	-$24.71M
YoY Change		-79.89%	745.43%
Interest Expense		$997.7K	$271.3K
YoY Change		267.73%	28.44%
% of Operating Profit
Other Income/Expense, Net		$1.070M	-$240.1K
YoY Change		-545.91%	17.11%
Pretax Income		-$3.898M	-$24.95M
YoY Change		-84.37%	697.68%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings		-$3.898M	-$24.95M
YoY Change		-84.37%	697.68%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.10	-$3.17
Diluted Earnings Per Share		-$0.10	-$3.17
COMMON SHARES
Basic Shares Outstanding	30.34M shares	30.34M shares	971.5M shares
Diluted Shares Outstanding		38.82M shares	7.881M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$69.63M	$5.130M
YoY Change	1257.29%	1134.98%
Cash & Equivalents	$67.41M	$5.126M
Short-Term Investments
Other Short-Term Assets	$2.651M	$867.9K
YoY Change	205.42%	503.31%
Inventory
Prepaid Expenses	$664.6K	$207.2K
Receivables
Other Receivables
Total Short-Term Assets	$79.81M	$15.29M
YoY Change	422.09%	469.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.517M	$55.28K
YoY Change	2643.51%	-35.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$26.31K	$8.309K
YoY Change	216.64%	0.0%
Total Long-Term Assets	$1.727M	$318.1K
YoY Change	442.98%	71.47%
TOTAL ASSETS
Total Short-Term Assets	$79.81M	$15.29M
Total Long-Term Assets	$1.727M	$318.1K
Total Assets	$81.54M	$15.60M
YoY Change	422.52%	443.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$780.0K	$1.631M
YoY Change	-52.19%	-21.1%
Accrued Expenses	$2.641M	$1.280M
YoY Change	106.36%	52.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$4.170M
YoY Change	-100.0%
Long-Term Debt Due	$0.00	$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$5.624M	$13.72M
YoY Change	-59.0%	123.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$108.1K	$190.0K
YoY Change	-43.13%	2208.63%
Total Long-Term Liabilities	$108.1K	$190.0K
YoY Change	-43.13%	2208.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.624M	$13.72M
Total Long-Term Liabilities	$108.1K	$190.0K
Total Liabilities	$5.732M	$13.91M
YoY Change	-58.79%	126.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$121.2M	-$99.96M
YoY Change	21.25%	75.85%
Common Stock	$197.0M	$101.7M
YoY Change	93.79%	89.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$75.80M	$1.695M
YoY Change
Total Liabilities & Shareholders Equity	$81.54M	$15.60M
YoY Change	422.52%	443.93%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$3.898M	-$24.95M
YoY Change	-84.37%	697.68%
Depreciation, Depletion And Amortization	$47.52K	$30.00K
YoY Change	58.4%	4.13%
Cash From Operating Activities	-$5.263M	-$4.060M
YoY Change	29.62%	97.41%
INVESTING ACTIVITIES
Capital Expenditures	$1.518M	$10.00K
YoY Change	15083.6%	-102.73%
Acquisitions
YoY Change
Other Investing Activities	$72.84K	$1.080M
YoY Change	-93.26%
Cash From Investing Activities	-$1.446M	$1.070M
YoY Change	-235.1%	-392.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	16.64M
YoY Change	-100.0%	-18216.49%
NET CHANGE
Cash From Operating Activities	-5.263M	-4.060M
Cash From Investing Activities	-1.446M	1.070M
Cash From Financing Activities	0.000	16.64M
Net Change In Cash	-6.708M	13.65M
YoY Change	-149.14%	-642.85%
FREE CASH FLOW
Cash From Operating Activities	-$5.263M	-$4.060M
Capital Expenditures	$1.518M	$10.00K
Free Cash Flow	-$6.781M	-$4.070M
YoY Change	66.61%	140.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	skye	Wind Down Costs WindDownCosts	0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-7902816	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	72809051	usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	45350	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-782265	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-11904	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-60647	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-570473	usd
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-95850	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10107460	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	5532266	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6603473	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14211044	usd
	skye	Common Stock Warrant Exercises CommonStockWarrantExercises	0	usd
	skye	Conversion Of Multi Draw Credit Agreement ConversionOfMultiDrawCreditAgreement	0	usd
	skye	Conversion Of Accrued Interest Due To Related Party ConversionOfAccruedInterestDueToRelatedParty	0	usd
	skye	Financing Of Insurance Premium FinancingOfInsurancePremium	203884	usd
	skye	Release Of Share Liability To Additional Paid In Capital ReleaseOfShareLiabilityToAdditionalPaidInCapital	241134	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3008054	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	131579	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3111500	usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	Skye Bioscience, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-0692882
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11250 El Camino Real,
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	410-0266
	dei	Security12g Title Security12gTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	SKYE
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9080202	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	664604	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	11650843	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43276	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	237983	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8309	usd
CY2023Q4	us-gaap	Assets Assets	11940411	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1155785	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14211044	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	78883393	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1828474	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3898297	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	75803375	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	160207	usd
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001516551
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30338290	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67412614	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1256453	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9080202	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	194259	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2650809	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1516612	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	184509	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	26310	usd
CY2024Q3	us-gaap	Assets Assets	81535660	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	780025	usd
CY2024Q3	skye	Interest Payable Related Parties Current InterestPayableRelatedPartiesCurrent	0	usd
CY2023Q4	skye	Interest Payable Related Parties Current InterestPayableRelatedPartiesCurrent	126027	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	903271	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	888381	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	234750	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2065658	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	998552	usd
CY2024Q3	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	1792337	usd
CY2023Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	6053468	usd
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4371998	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	82932	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	72038	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5624223	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13900999	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	108062	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	171230	usd
CY2024Q3	us-gaap	Liabilities Liabilities	5732285	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14072229	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30338290	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12349243	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12349243	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	30338	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12349	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	196976230	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	102238382	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121203193	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104382549	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	75803375	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2131818	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81535660	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11940411	usd
CY2024Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4883337	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1254653	usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10908538	usd
	dei	Entity File Number EntityFileNumber	000-55136
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2478179	usd
CY2024Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	6434447	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	83556563	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5019531	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1921617	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4971004	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	0	usd
CY2023Q1	skye	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	282905	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2980521	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5167520	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4780569	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	102871	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-7789198	usd
CY2023Q3	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	265053	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11734947	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	21609586	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	925550	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-24945834	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1695258	usd
	dei	Document Type DocumentType	10-Q
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1119929	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	79808229	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30338290	shares
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4227967	usd
CY2024Q3	skye	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	0	usd
CY2023Q3	skye	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	21215214	usd
	skye	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	0	usd
	skye	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	21215214	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4638927	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2235899	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13171547	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5357577	usd
CY2024Q3	skye	Gain Loss From Estimated Legal Contingency GainLossFromEstimatedLegalContingency	4553468	usd
CY2023Q3	skye	Gain Loss From Estimated Legal Contingency GainLossFromEstimatedLegalContingency	0	usd
	skye	Gain Loss From Estimated Legal Contingency GainLossFromEstimatedLegalContingency	4553468	usd
	skye	Gain Loss From Estimated Legal Contingency GainLossFromEstimatedLegalContingency	151842	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	4968796	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	24705766	usd
	us-gaap	Operating Expenses OperatingExpenses	19526617	usd
	us-gaap	Operating Expenses OperatingExpenses	30648916	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4968796	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24705766	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19526617	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30648916	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	-90766	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	271307	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	796222	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	476135	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	907697	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	16562	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2296488	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	49669	usd
CY2024Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	72837	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1217978	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-307086	usd
CY2024Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1383285	usd
CY2023Q3	skye	Wind Down Costs WindDownCosts	-14677	usd
	skye	Wind Down Costs WindDownCosts	0	usd
	skye	Wind Down Costs WindDownCosts	455504	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-801	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2200	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1070499	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-240068	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2716044	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2572338	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3898297	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24945834	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16810573	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33221254	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10071	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3600	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3898297	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-24945834	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16820644	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33224854	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.38
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.38
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38819387	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7880546	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35317352	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5207411	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38819387	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7880546	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35317352	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5207411	shares
	us-gaap	Net Income Loss NetIncomeLoss	-16820644	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33224854	usd
	us-gaap	Depreciation Depreciation	123347	usd
	us-gaap	Depreciation Depreciation	95880	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6228270	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	394657	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-3	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	599006	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	102400	usd
	skye	Vendor Deposit Write Down VendorDepositWriteDown	325610	usd
	skye	Vendor Deposit Write Down VendorDepositWriteDown	0	usd
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	-4553468	usd
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	7009	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1217978	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-307086	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-10794	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1383285	usd
	skye	Accrued Interest Conversion Expense AccruedInterestConversionExpense	0	usd
	skye	Accrued Interest Conversion Expense AccruedInterestConversionExpense	15952	usd
	skye	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	0	usd
	skye	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	21215214	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	470345	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1606490	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	236779	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	18000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-375760	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-112021	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-113601	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	14889	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-52274	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1109443	usd
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17064377	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1217978	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1554003	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5533	usd
	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	0	usd
	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	-1076740	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-336025	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4973684	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	6434447	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	265053	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	83556563	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11734947	usd
	skye	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
	skye	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	-6026	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	236681	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83556563	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16465924	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	66156161	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12961937	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10336655	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1249107	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76492816	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67412614	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5126245	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9080202	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9084799	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76492816	usd
	skye	Common Stock Warrant Exercises CommonStockWarrantExercises	282905	usd
	skye	Conversion Of Multi Draw Credit Agreement ConversionOfMultiDrawCreditAgreement	1565470	usd
	skye	Conversion Of Accrued Interest Due To Related Party ConversionOfAccruedInterestDueToRelatedParty	31766	usd
	skye	Financing Of Insurance Premium FinancingOfInsurancePremium	0	usd
	skye	Release Of Share Liability To Additional Paid In Capital ReleaseOfShareLiabilityToAdditionalPaidInCapital	0	usd
	skye	Stock Issued For Assets Net Of Equity Issuance Costs StockIssuedForAssetsNetOfEquityIssuanceCosts	0	usd
	skye	Stock Issued For Assets Net Of Equity Issuance Costs StockIssuedForAssetsNetOfEquityIssuanceCosts	20532846	usd
	skye	Noncash Conversion Of Convertible Note NoncashConversionOfConvertibleNote	4971004	usd
	skye	Noncash Conversion Of Convertible Note NoncashConversionOfConvertibleNote	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2131818	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-307086	usd
CY2024Q3	skye	Disposal Group Including Discontinued Operation Consideration Receivable Interest Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableInterestRate	0.08
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1616241	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	138710	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	99629	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	95434	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1516612	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43276	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47519	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69873	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12788	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38107	usd
CY2024Q3	skye	Prepaid Clinical Expenses PrepaidClinicalExpenses	64878	usd
CY2023Q4	skye	Prepaid Clinical Expenses PrepaidClinicalExpenses	61352	usd
CY2024Q3	skye	Prepaid Financial Advisory Service Agreement PrepaidFinancialAdvisoryServiceAgreement	284170	usd
CY2023Q4	skye	Prepaid Financial Advisory Service Agreement PrepaidFinancialAdvisoryServiceAgreement	0	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	315556	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	132907	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	664604	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	194259	usd
CY2024Q3	skye	Tax Rebate Current TaxRebateCurrent	9033	usd
CY2023Q4	skye	Tax Rebate Current TaxRebateCurrent	540604	usd
CY2024Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	2216427	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	403439	usd
CY2024Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3678	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	158242	usd
CY2024Q3	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	421671	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	17644	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2650809	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1119929	usd
CY2024Q3	skye	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	1220041	usd
CY2023Q4	skye	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	467784	usd
CY2024Q3	skye	Legal Professional Fee Accrual LegalProfessionalFeeAccrual	370359	usd
CY2023Q4	skye	Legal Professional Fee Accrual LegalProfessionalFeeAccrual	258213	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	180897	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	410512	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	69468	usd
CY2024Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	64746	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	22190	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2065658	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	998552	usd
CY2024Q3	skye	Class Of Warrant Or Right Warrants Vested And Outstanding ClassOfWarrantOrRightWarrantsVestedAndOutstanding	11950106	shares
CY2024Q3	skye	Interest Expense Related Party Stated Rate InterestExpenseRelatedPartyStatedRate	53425	usd
CY2023Q3	skye	Interest Expense Related Party Stated Rate InterestExpenseRelatedPartyStatedRate	60274	usd
	skye	Interest Expense Related Party Stated Rate InterestExpenseRelatedPartyStatedRate	302741	usd
	skye	Interest Expense Related Party Stated Rate InterestExpenseRelatedPartyStatedRate	76227	usd
CY2024Q3	skye	Insurance Premium Expense InsurancePremiumExpense	0	usd
CY2023Q3	skye	Insurance Premium Expense InsurancePremiumExpense	2162	usd
	skye	Insurance Premium Expense InsurancePremiumExpense	0	usd
	skye	Insurance Premium Expense InsurancePremiumExpense	5764	usd
CY2024Q3	skye	Legal Fees Interest Expense LegalFeesInterestExpense	-384897	usd
CY2023Q3	skye	Legal Fees Interest Expense LegalFeesInterestExpense	-23320	usd
	skye	Legal Fees Interest Expense LegalFeesInterestExpense	-234751	usd
	skye	Legal Fees Interest Expense LegalFeesInterestExpense	158851	usd
CY2024Q3	skye	Bond Premium BondPremium	59929	usd
CY2023Q3	skye	Bond Premium BondPremium	59930	usd
	skye	Bond Premium BondPremium	59929	usd
	skye	Bond Premium BondPremium	59930	usd
CY2024Q3	skye	Premium On Irrevocable Letter Of Credit PremiumOnIrrevocableLetterOfCredit	69297	usd
CY2023Q3	skye	Premium On Irrevocable Letter Of Credit PremiumOnIrrevocableLetterOfCredit	69861	usd
	skye	Premium On Irrevocable Letter Of Credit PremiumOnIrrevocableLetterOfCredit	69297	usd
	skye	Premium On Irrevocable Letter Of Credit PremiumOnIrrevocableLetterOfCredit	69861	usd
CY2024Q3	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
CY2023Q3	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
	us-gaap	Interest Expense Other InterestExpenseOther	3102	usd
CY2024Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108417	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	99587	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	582550	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	99587	usd
CY2024Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3063	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2813	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	16456	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2813	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	-90766	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	271307	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	796222	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	476135	usd
CY2024Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	5000	shares
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1921617	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	160207	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6228270	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	394657	usd
CY2024Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	274019	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	274019	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11758346	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M9D
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3898297	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3898297	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24945834	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24945834	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16820644	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16820644	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-33224854	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33224854	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38819387	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38819387	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7880546	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7880546	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35317352	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35317352	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5207411	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5207411	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.17
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.38
CY2024Q3	skye	Loss Contingency Net Cash Received To Cover Legal Expenses LossContingencyNetCashReceivedToCoverLegalExpenses	5000000	usd
CY2024Q3	skye	Operating Lease Area Of Leased Space OperatingLeaseAreaOfLeasedSpace	2077	sqft
CY2024Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y2M
CY2024Q3	skye	Operating Leases Monthly Rental Expense OperatingLeasesMonthlyRentalExpense	9000	usd
CY2024Q3	skye	Lessee Operating Lease Annual Rent Increase Percent LesseeOperatingLeaseAnnualRentIncreasePercent	0.03
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
skye-20240930_cal.xml	Edgar Link	unprocessable
0001516551-24-000110-index-headers.html	Edgar Link	pending
0001516551-24-000110-index.html	Edgar Link	pending
0001516551-24-000110.txt	Edgar Link	pending
0001516551-24-000110-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
skye-20240930.htm	Edgar Link	pending
skye-20240930.xsd	Edgar Link	pending
skye-20240930xex311xsectio.htm	Edgar Link	pending
skye-20240930xex312xsectio.htm	Edgar Link	pending
skye-20240930xex321xsectio.htm	Edgar Link	pending
skye-20240930xex322xsectio.htm	Edgar Link	pending
skyeex101bio-amendedandres.htm	Edgar Link	pending
skye-20240930_def.xml	Edgar Link	unprocessable
skye-20240930_lab.xml	Edgar Link	unprocessable
skye-20240930_pre.xml	Edgar Link	unprocessable
skye-20240930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKYE
Skye Bioscience, Inc. Stock $skye

2024 Q4 Form 10-Q Financial Statement

#000151655124000110 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE Skye Bioscience, Inc. Stock $skye

2024 Q4 Form 10-Q Financial Statement

#000151655124000110 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE
Skye Bioscience, Inc. Stock $skye